RUBY Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 gruod. 2023 @ 22:49):

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases...

Stats
Dzisiejszy wolumen	755 858
Średni wolumen	99 535.00
Kapitalizacja rynkowa	5.16M
EPS	$0 ( 2024-02-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0286
ATR14	$0.00200 (3.51%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-24	Appelhans Dannielle	Sell	10 385	Common Stock
2023-02-01	Cagnoni Pablo J	Sell	8 448	Common Stock
2023-01-31	Appelhans Dannielle	Sell	7 500	Restricted Stock Units
2023-01-31	Appelhans Dannielle	Buy	7 500	Common Stock
2023-02-01	Appelhans Dannielle	Sell	3 878	Common Stock

INSIDER POWER
20.47
Last 96 transactions
Buy: 4 525 378 \| Sell: 349 777

Wolumen Korelacja

Długi: 0.54 (weak)

Krótki: 0.36 (neutral)

Signal:(87.518) Neutral

Rubius Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
DFPH	0.979
VOSOU	0.978
LWAC	0.97
LWACU	0.968
GSMG	0.961
AGBA	0.943
MRAC	0.939
PPGHU	0.913
ALVR	0.895
ARQT	0.889

10 Najbardziej negatywne korelacje
ESAC	-0.962
CTAC	-0.961
MCAE	-0.952
CMLT	-0.918
BCYP	-0.914
KURI	-0.894
ICLK	-0.891
GIAC	-0.889
MACQU	-0.882
GLADL	-0.882

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rubius Therapeutics Inc Korelacja - Waluta/Towar

-0.07
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.69
( moderate negative )

-0.48
( neutral )

Rubius Therapeutics Inc Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.56

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-2.56

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.23

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.08

Financial Reports:

No articles found.

Rubius Therapeutics Inc

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.